Improved IBDQ at week 52 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Adalimumab (3 RCTs; 37 participants) · surgically induced remission in Crohn's disease
The intervention may leads to lower adalimumab (3 RCTs; 37 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Adalimumab (1 RCT; 16 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes adalimumab (1 RCT; 16 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Adalimumab (2 RCTs; 26 participants) · surgically induced remission in Crohn's disease
The intervention may leads to lower adalimumab (2 RCTs; 26 participants) (low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Intervention not reported
OutcomesAnalysis 1.4 · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Failure to achieve clinical remission · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical remission (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (70‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (70‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (100‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (100‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Endoscopic response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease
1 finding from 1 review
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review